Syndrome  >>  Aptivus (tipranavir)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

10 Trials

Remove FilterRemove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Aptivus (tipranavir) / Boehringer Ingelheim
NCT02249130: Tipranavir Dose-response Study Using a Prototype Self-emulsifying Drug Delivery System (SEDDS) Formulation in Treatment-naive HIV-1 Infected Patients Report on the Post-study Option, a Treatment of Triple Therapy With Delavirdine, ZDV and 3TC Without Tipranavir

Completed
2
18
US, RoW
Tipranavir (TPV), Ritonavir (RTV), Delavirdine (DLV), Zidovudine (ZDV), Lamivudine (3TC), Stavudine (d4T)
Boehringer Ingelheim
HIV Infections
04/00
 
NCT02238314: Exploratory Study of Tipranavir and Ritonavir in Multiple Protease Inhibitor-experienced HIV Patients

Completed
2
41
US
Tipranavir low dose, Tipranavir high dose, Ritonavir, Nucleoside Reverse Transcriptase Inhibitor (NRTI), Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)
Boehringer Ingelheim
HIV Infections
08/01
 
NCT02239835: Tipranavir and Ritonavir vs. Saquinavir and Ritonavir Used With Two Nucleoside Reverse Transcriptase Inhibitors in Single Protease Inhibitor-experienced HIV-1 Patients

Terminated
2
79
US, Europe
Tipranavir (TPV) low dose, Tipranavir (TPV) high dose, Ritonavir low dose, Ritonavir high dose, Saquinavir
Boehringer Ingelheim
HIV Infections
11/01
 
NCT00275444: 3 TPV/RTV Doses in Multiple ARV Experienced Patients - Tipranavir Dose Defining Study

Completed
2
216
Europe, Canada, US, RoW
Tipranavir
Boehringer Ingelheim
HIV Infections
01/03
 
NCT00056641: Dual Boosted - Protease Inhibitor (PI) Pharmacokinetics (PK) Trial (Tipranavir / Ritonavir) in Highly Treatment-experienced HIV-1 Infected Patients

Completed
2
328
Europe, Canada, US, RoW
tipranavir, ritonavir, saquinavir, amprenavir, lopinavir
Boehringer Ingelheim
HIV Infections
01/04
 
NCT00144105: A Randomised Trial to Evaluate the Antiviral Efficacy and Safety of Treatment With 500 mg Tipranavir (TPV) Plus 100 mg or 200 mg Ritonavir (RTV) p.o. BID in Comparison to 400 mg Lopinavir (LPV) Plus 100 mg RTV p.o. BID in Combination With Standard Background Regimen in ARV Therapy naïve Patients.

Terminated
2
562
Canada, Europe, RoW
TPV500mg/RTV200mgBID, TPV500mg/RTV100mgBID, LPV400mg/RTV100mgBID
Boehringer Ingelheim
HIV Infections
11/06
 
NCT00294372 / 2005-004698-39: Phase II Study on the Antiviral Activity and Safety of BILR 355 BS in HIV-1 Infected, NNRTI-treated Patients

Terminated
2
36
Europe
BILR 355 BS, Placebo
Boehringer Ingelheim
HIV Infections
09/07
 
NCT00530920 / 2006-005256-33: Tipranavir/Ritonavir Low Dose Pharmacokinetics in Treatment Naive Patients

Completed
2
85
Europe
tipranavir, ritonavir
Boehringer Ingelheim
HIV Infections
05/08
 
NCT02251223: Effects of Tipranavir/Ritonavir on the Pharmacokinetic Characteristics of Triple Drug Nucleoside and Non-nucleoside Reverse Transcriptase Inhibitor Therapy in HIV-1-infected Subjects

Completed
1/2
208
US, Europe
Tipranavir low dose, Tipranavir medium dose, Tipranavir high dose, Ritonavir low dose, Ritonavir high dose
Boehringer Ingelheim
HIV Infections
02/02
 
NCT02229760: Effect of Steady State TPV/r on Intracellular Concentrations of Zidovudine and Carbovir for Patients With HIV

Terminated
1/2
3
US
Tipranavir capsules, Ritonavir capsules
Boehringer Ingelheim
HIV Infections
09/07
 

Download Options